Program
SHR 3201
A development code. Also written as “SHR 3201 Injection”.
Its studies are mostly in Alzheimer Disease, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 11 open or running | phase 1since Oct 16, 2026 | Oct 16, 2026 | Jan 2027phase 1 · NCT07889349 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 16, 2026First study: phase 1 study in Alzheimer DiseaseFirst studyNCT07889349 · 50 planned · China
Ahead
- Jan 2027Primary completion: phase 1 study in Alzheimer DiseaseNCT07889349
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07889349Alzheimer Disease · China | 1 | Not yet recruiting | Jan 2027 | 50 |
How it is read
Names in the registry
- “SHR 3201 Injection”, 1 entry
Codes read as this program: SHR3201.
Conditions, from the studies’ own filings
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.